Vascugel enters CABG (coronary artery bypass graft) trials
This article was originally published in Clinica
Executive Summary
Curis has begun a phase I clinical trial in the US of its cellular implant for preventing thrombosis and restenosis following cardiovascular surgical procedures. Vascugel, a biodegradable product containing human endothelial cells, is being assessed in patients undergoing coronary artery bypass graft (CABG) surgery.